Amgen Inc.
AMGN
You’ve read what changed. Here’s whether the market is confirming it.
Jodie situation report
Amgen Inc.'s move is spreading beyond its market group.
AMGN accounts for 9.0% of the group's measured movement across 7.5 effective names. all 12 measured members are rising in raw terms, but 9 of 12 SPY-adjusted paths align to the upside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
GILD, MRK, GSK moved materially before AMGN. AMGN crossed its material path threshold at 09:50 ET, 5 minutes after the first measured mover. HALO, EXEL, INCY followed.
- Revenue increased 9.5% versus the comparable filing period.
11 of 15 members in Biopharmaceuticals and Care are active. 5 of 8 disclosed connections are confirming.
- At least 10 of 15 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- SNY remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.
Latest filing assessment
Fundamentals strengthened in the latest filing
10-Q filed 2026-08-05 against the comparable filing from 2025-08-06.
Capital and cash conversion
Reported investment and cash context
- Capital spending YoY
- +57.1%
- Capital spending / revenue
- +6.6%
- Free-cash-flow margin
- +26.6%
- FCF margin change
- +9.9 pts
Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.
What improved
- Revenue increased 9.5% versus the comparable filing period.
- Operating margin improved 6.0 percentage points.
- Net income increased 65.9% versus the comparable filing period.
What weakened
No thresholded deterioration was identified.
Filing receipts
“40 Nonoperating expenses/income and income taxes Nonoperating expenses/income and income taxes were as follows (dollar amounts in millions): Three months ended June 30, Six months ended June 30, 2026 2025 2026 2025 Interest expense, net $ (673) $ (694) $ (1,330) $ (1,417) Other (expense) income, net $ (73) $ (394) $ 2 $ 1,124 Provision for income taxes $ 393 $ 136 $ 658 $ 379 Effective tax rate 14.2 % 8.7 % 13.6 % 10.7 % Interest expense, net Interest expense, net, decreased for the three and six months ended June 30, 2026, primarily due to lower average debt outstanding.”
“Investing Cash used in investing activities during the six months ended June 30, 2026 and 2025, was primarily due to capital expenditures of $1.2 billion and $780 million, respectively, including construction costs for new plants and expansion of manufacturing capacity.”
“Prolia Total Prolia sales by geographic region were as follows (dollar amounts in millions): Three months ended June 30, Six months ended June 30, 2026 2025 Change 2026 2025 Change Prolia — U.S. $ 478 $ 745 (36) % $ 939 $ 1,465 (36) % Prolia — ROW 281 377 (25) % 547 756 (28) % Total Prolia $ 759 $ 1,122 (32) % $ 1,486 $ 2,221 (33) % The decreases in global Prolia sales for the three and six months ended June 30, 2026 were primarily driven by lower volume of 20% and 19%, respectively, and lower net selling price of 12% and 11%, respectively.”
Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.